[go: up one dir, main page]

AU7476800A - Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 - Google Patents

Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48

Info

Publication number
AU7476800A
AU7476800A AU74768/00A AU7476800A AU7476800A AU 7476800 A AU7476800 A AU 7476800A AU 74768/00 A AU74768/00 A AU 74768/00A AU 7476800 A AU7476800 A AU 7476800A AU 7476800 A AU7476800 A AU 7476800A
Authority
AU
Australia
Prior art keywords
protein tyrosine
tyrosine phosphatase
ptpases
asp residue
cell protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74768/00A
Inventor
Henrik Sune Andersen
Frank Urban Axe
Yu Ge
Thomas Kruse Hansen
Daniel Dale Holsworth
Lars Fogh Iverson
Todd Kevin Jones
Luke Milburn Judge
Jesper Lau
Niels Peter Hundahl Moller
Ole Hvilsted Olsen
William Charles Ripka
Barry Zvi Shapira
Roy Teruyuki Uyeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Ontogen Corp
Original Assignee
Novo Nordisk AS
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Ontogen Corp filed Critical Novo Nordisk AS
Publication of AU7476800A publication Critical patent/AU7476800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU74768/00A 1999-09-10 2000-09-11 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 Abandoned AU7476800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA199901279 1999-09-10
DKPA199901279 1999-09-10
US15664199P 1999-09-29 1999-09-29
US60156641 1999-09-29
PCT/US2000/024761 WO2001017516A2 (en) 1999-09-10 2000-09-11 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48

Publications (1)

Publication Number Publication Date
AU7476800A true AU7476800A (en) 2001-04-10

Family

ID=26065517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74768/00A Abandoned AU7476800A (en) 1999-09-10 2000-09-11 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48

Country Status (3)

Country Link
EP (1) EP1214060A2 (en)
AU (1) AU7476800A (en)
WO (1) WO2001017516A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301516B1 (en) * 2000-07-07 2006-03-22 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
AU2001268951A1 (en) * 2000-07-07 2002-01-21 Novo-Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
DE10037310A1 (en) * 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
US6972340B2 (en) 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
US20020169157A1 (en) * 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
CA2326952A1 (en) * 2000-11-27 2002-05-27 The Hospital For Sick Children T cell protein tyrosine phosphatase
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2006052542A2 (en) * 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US9365608B2 (en) 2007-09-06 2016-06-14 Ohr Pharmaceutical, Inc. Method for treating diabetes
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
ES2978959T3 (en) 2009-12-04 2024-09-23 Sumitomo Pharma America Inc Multicyclic compounds and methods of using them
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2838907T (en) 2012-04-20 2019-08-05 Ohr Pharmaceutical Inc Aminosteroids for the treatment of a ptp1b associated disease
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
CN116808023A (en) 2017-02-16 2023-09-29 桑诺维恩药品公司 How to treat schizophrenia
CA3070993A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
JP7453148B2 (en) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク Salts, crystalline forms, and their production methods
EA202190011A1 (en) * 2018-06-21 2021-04-27 Юсб Байофарма Срл THIOPHENE DERIVATIVES FOR THE TREATMENT OF IgE DISORDERS
WO2020072126A2 (en) * 2018-08-07 2020-04-09 Dana-Farber Cancer Institute, Inc. Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
KR20210139376A (en) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 Salts of isochromanyl compounds, and crystalline forms thereof, methods of preparation, therapeutic uses and pharmaceutical compositions
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953468A (en) * 1974-03-15 1976-04-27 The Upjohn Company 3-Cyano thiophen-2-yl oxamic acid and derivatives
GB1583679A (en) * 1977-10-11 1981-01-28 Bristol Myers Co Thieno (2,3-d) pyrimidine and other thiophene-derived anti-allergic agents
JP2000511883A (en) * 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ Modulators of molecules with phosphotyrosine recognition units
AU2713799A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
WO1999046236A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1062218A1 (en) * 1998-03-12 2000-12-27 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
KR20010041811A (en) * 1998-03-12 2001-05-25 온토젠 코포레이션 Modulators of protein tyrosine phosphatases
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1214325B1 (en) * 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
JP2003509429A (en) * 1999-09-10 2003-03-11 ノボ ノルディスク アクティーゼルスカブ Modulator of protein tyrosine phosphatase (PTPase)

Also Published As

Publication number Publication date
WO2001017516A2 (en) 2001-03-15
WO2001017516A3 (en) 2001-11-08
EP1214060A2 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
AU7476800A (en) Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
AU4908699A (en) Use of pit emulsions
AU4055600A (en) Impaction substrate and methods of use
AU8007000A (en) Integrated forms and method of making such forms
AU4231197A (en) Hppd gene and inhibitors
AU6604898A (en) Catheters and endoscopes comprising optical probes and bioptomes and methods of using the same
AU1795500A (en) Electronic couponing system and methods for use of same
AU2998299A (en) Improved protective coatings for metals and other surfaces
AU8746998A (en) Object observation device and object observation method
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
AU9247398A (en) Liquid-cristal display and the method of its fabrication
AU5115999A (en) Surgical support device and method of using the same
AU2637299A (en) Method and kit for the detection of explosives
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
AU5134599A (en) Expression of functional eukaryotic proteins
AU3606799A (en) Method and arrangement for measuring the structures of an object
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU3516899A (en) Method and probes for the detection of chromosome aberrations
AU4992299A (en) Uncoupling protein 4 (ucp-4) and methods of use
AU5122500A (en) Detection of biological warfare agents
AU6271598A (en) Targeted modification of the ccr-5 gene
AU2467299A (en) Protective split sleeve and method for making it
AU3266999A (en) Nanotribological probe microscope
AU5634099A (en) Composition for the removal of biological and organic substances
AU3972899A (en) Analysis of gene family expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase